Increased platelet activation in young patients with prehypertension.

Mean platelet volume (MPV) and sP-selectin levels are considered as indicators of platelet activation. In this study, we assessed platelet activation in prehypertensive patients by comparing MPV and sP-selectin levels of these patients with healthy conrols. The study population consisted of 25 newly diagnosed prehypertensive individuals (18 men, mean age = 34 ± 6 y) and 25 healthy control subjects (16 men, mean age = 33 ± 6 y) eligible for the current study. Blood pressure (BP) , lipid profile, plasma glucose, HOMA-IR values, sP-selectin levels, platelet counts, and MPV were measured in both groups. Other than systolic blood pressure (SBP) and diastolic blood pressure (DBP), baseline demographic characteristics of both groups were similar. No significant difference was found between the platelet counts of the two groups. Despite comparable platelet counts, platelet activation parameters were found significantly higher in the prehypertensives. Prehypertensives had larger a MPV value compared to that of the control group (8.24 ± 0.46 fl vs. 7.70 ± 0.64 fl; P = 0.001) and plasma sP-selectin levels were also significantly higher in the prehypertensive patients (163.60 ± 41.21 ng/ml vs. 132.80 ± 36.46; P = 0.007). Spearman correlation analysis revealed moderate positive correlation between SBP and platelet activation parameters (for SBP and MPV, r = 0.60, p = 0.001; for SBP and sP-selectin r = 0.51, p = 0.009). Prehypertension causes platelet activation as evidenced by increased MPV and plasma sP-selectin levels. Increased platelet activation might be related to increased vascular thrombotic risk in those patients.

Alpha tocopherol use in the management of diabetic cardiomyopathy: lessons learned from randomized clinical trials.

Although animal studies suggested that there may be a role for antioxidants (especially alpha-tocopherol) as therapy for heart failure (HF), the results obtained from human trials are disappointing. The variability in the response to antioxidant therapy may be due to genetic polymorphisms in enzymes involved in oxidative stress. We strongly believe that we do not have enough data supporting the use of antioxidant treatment in the management of HF patients, including a diabetic subset.

The beneficial effects of angiotensin-converting enzyme inhibitors on serum asymmetric dimethylarginine levels in the patients with cardiovascular disease.

ACEI and AT1 receptor antagonists are the drugs most consistently shown to reduce ADMA level in humans. Unfortunately, most of the human studies addressing the effect of pharmacotherapy on ADMA metabolism were accomplished on small patient subgroups and were relatively shortlasting. Besides, L-arginine was rarely measured in most studies, whereas L-arginine/ADMA ratio may be more important for NO synthase function than ADMA itself, and arginine concentration may be either increased or decreased by pharmacotherapy. We strongly believe that agents affecting ADMA more specifically (protein arginine methyltransferases inhibitors or dimethylarginine dimethylaminohydrolase inducers) deserve further investigation.

Stent fracture: a new villain of the village.

Stent strut fracture (SSF) may be an important complication after drug-eluting stent (DES) implantation particularly in patients undergoing sirolimus-eluting stent (SES) implantation. The occurrence of SSF at 6 to 9 months after the SES implantation, which was relatively common, resulted in a higher rate of focal in-stent restenosis. Although this angiographic unfavorable outcome did not lead to an increased risk of adverse cardiac events in the current study, we believe that large-scale prospective studies are needed to elucidate the exact pathophysiology and clinical sequela of the stent strut fracture, including bare metal stents.

Stress-induced (Takotsubo) cardiomyopathy: a transient disorder.

Once the diagnosis of Takotsubo cardiomyopathy has been made, treatment should be based upon the patient's overall clinical condition. Up to now, there has been no controlled data to guide the optimal medical regimen, but it is reasonable to treat these patients with standard medications for left ventricular systolic dysfunction during acute phase. This includes aspirin, beta-blockers, ACE-inhibitors, and diuretics as necessary for volume overload. Since this type of cardiomyopathy is a transient disorder, the appropriate duration of therapy is not known. Although the current study demonstrates that the use of beta-blockers, aspirin, ACE inhibitors and calcium channel blockers does not seem to be indicated for chronic treatment of Takotsubo cardiomyopathy, we strongly believe that we need to achieve the data which will be obtained from large scale prospective studies in the near future to assess the clinical significance of chronic medical treatment.

The clinical presentation of restenosis after bare metal stent implantation: behind a facade of benignity.

Contrary to common belief, bare metal in-stent restenosis (ISR) seems to be not a benign clinical entity. Thus,we believed that continued efforts are warranted to prevent bare metal ISR, including aggressive use of drug-eluting stent (DES) to decrease the incidence of acute coronary syndromes. However, despite improved outcomes with DES, bare metal stent (BMS) will continue to play a role for both clinical and economic reasons and we feel that there is still a future for BMS.

Impact of admission glomerular filtration rate on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction.

AIMS: We aimed to investigate the impact of admission estimated glomerular filtration rates (eGFR) on the development of poor myocardial perfusion after primary percutaneous coronary intervention (pPCI) in patients presenting with acute ST-segment-elevation myocardial infarction (STEMI). MATERIALS AND METHODS: Study population consisted of 80 patients with STEMI (64 men, mean age=67.5+/-6.6 years) undergoing pPCI. Myocardial perfusion was evaluated by using thrombolysis in myocardial infarction (TIMI) myocardial perfusion grade (TMPG). Patients were divided into two groups according to TMPG after pPCI. Group 1 and 2 consisted of 40 patients with TMPGs 0-1 and 40 patients with TMPGs 2-3, respectively. GFR was calculated based on the abbreviated Modification of Diet in Renal Disease study equation. RESULTS: Admission serum creatine kinase-MB isoenzyme (CKMB) levels and the percentage of lower eGFR (<60 ml/min/1.73 m2) values of the patients with TMPGs 0-1 were significantly higher than those of the patients with TMPGs 2-3 after primary PCI (P=0.007, P<0.001, respectively). Univariate analysis identified pain-to-balloon time, eGFR lower than 60 ml/min/1.73 m2, peak CKMB, and TIMI flow grade 0/1 as the predictors of poor myocardial perfusion. In multivariate analysis peak CKMB, left ventricular ejection fraction less than 35%, admission TIMI flow grade 0/1, lower eGFR and pain-to-balloon time continued to have statistically significant independent association with poor myocardial perfusion in the model. Adjusted odds ratios were calculated as 12.05 for low eGFR [P=0.005; confidence interval (CI): 2.11-68.70], 8.10 for admission TIMI grade 0/1 (P=0.04; CI: 1.37-47.91), 7.04 for pain-to-balloon time (P<0.001; CI: 2.37-20.90), 6.76 for low left ventricular ejection fraction (P=0.03; CI: 1.12-40.61), and 1.02 for CKMB (P=0.01; CI: 1.00-1.04). CONCLUSION: Decreased GFR on admission in patients with STEMI is independently associated with the risk of poor myocardial perfusion following after primary PCI.

The comparative effects of metoprolol and perindopril on aortic elasticity in young patients with prehypertension.

OBJECTIVES: It has been recently demonstrated that aortic elasticity is impaired in young patients with prehypertension compared with healthy controls. Accordingly, the purpose of the current study was to analyze the comparative effects of metoprolol and perindopril on aortic elasticity in young patients with prehypertension after 6 months of therapy. MATERIAL AND METHODS: Fifty newly diagnosed patients with hypertension, who were in the prehypertension category according to the Joint National Committee seventh report, were enrolled in this blind, randomized, prospective study. After baseline clinical assessment, patients were randomly assigned to 4 mg daily dose of perindopril (group I, n=27, 18 male, median age=35 years) or 100 mg daily dose of metoprolol succinate (group II, n=28, 16 male, median age=33 years) for 6 months. Aortic strain, distensibility, and stiffness indexes were calculated from aortic diameters measured by echocardiography and blood pressures simultaneously measured by sphygmomanometry before and after treatment. RESULTS: When the median aortic distensibility and strain indexes after 6 months of therapy were analyzed, aortic distensibility and strain indexes of both treatment arms were found to be significantly higher than those of the pretreatment period. In contrast, the posttreatment aortic stiffness indexes of both groups were significantly lower compared with those of pretreatment period. No statistical difference was found between pretreatment and posttreatment aortic elasticity parameters of both groups. Importantly, no statistically significant difference was found between the percentage change from baseline of metoprolol and perindopril groups regarding aortic elasticity parameters (aortic distensibility: 38.1 vs. 37.9%, respectively, P=0.86; aortic strain: 37.7 vs. 37.9%, respectively, P=0.44; stiffness index: -20.0 vs. -23.9%). CONCLUSION: The current study revealed that early pharmacological intervention had strong beneficial effects on aortic elasticity in patients with prehypertension despite the fact that neither metoprolol nor perindopril was superior to the other.

ST elevation during treadmill exercise test in a young patient with slow coronary flow: a case report and review of literature.

The coronary slow flow phenomenon is an angiographic curiosity characterized by delayed distal vessel opacification provided that the presence of significant epicardial coronary disease is excluded. Slow flow phenomenon in epicardial coronary arteries is not infrequent finding during routine coronary angiography. However, the clinical features of patients with slow flow phenomenon have not been extensively studied. ST elevation in leads without Q waves during exercise testing has not been previously reported in patients with slow flow phenomenon. In the current case, we report a 29-year-old man with angiographically normal coronary arteries associated with slow coronary flow in the absence of any significant obstructive coronary artery disease and no evidence of epicardial coronary artery spasm in whom ST segment elevation in leads I and aVL was observed at maximal exercise of treadmill test.

Atrioventricular nodal reentrant tachycardia ablated from left atrial septum: clinical and electrophysiological characteristics and long-term follow-up results as compared to conventional right-sided ablation.

Radiofrequency catheter ablation or modification of the slow pathway is almost always performed on the right atrial side of the interatrial septum, however, this is not possible in rare cases. We evaluated the clinical and electrophysiological characteristics and long-term follow-up results of patients whose AVNRT could only be ablated from the left posterior atrial septum after repeated unsuccessful attempts on the right atrial side and to observe if they differ from those undergoing ablation with the conventional right-sided approach. Of 587 cases with symptomatic typical AVNRT, 9 patients (1.5%) in whom RF energy delivered to the right atrial septum with the integrated approach failed to ablate or modify the slow pathway were enrolled in the study group (group 1) while the others served as controls (group 2). There was no significant difference between the groups regarding clinical characteristics, dual AV nodal physiology, sinus cycle lengths, AH and HV intervals, procedural complication rates, or recurrence rates in the mean follow-up duration of 34 +/- 11 months. Only tachycardia cycle length (TCL) was significantly higher in group 1 than in group 2, which was mainly due to the difference in AH intervals (P < 0.001 for both). Slow pathway ablation was performed at the posteroseptal aspect of the mitral annulus in 6 and the midseptal aspect in 2 cases. In 1 case, attempts at ablation on the left atrial septum also failed. When the conventional right-sided approach fails to ablate or modify the slow pathway conduction, left-sided ablation can safely and effectively be employed, with success rates and long-term follow-up results comparable to the conventional right-sided approach.